Reflexive drugs have earned full rights to REV102 and potential oral therapy for rare bone disorder hypolingalis

Recursion Pharmaceuticals Inc. (NASDAQ:rxrx) is one of According to analysts, the best small cap AI stock to buy. July 8th, Rallybio Corporation (NASDAQ:rlyb) announced a decisive agreement to sell interest in REV102 to joint venture Recursion Pharmaceuticals. The agreement is valued at up to $25 million, with $7.5 million in advance shares and short-term milestone payments.

REV102 is a currently preclinical developmental ENPP1 inhibitor for the treatment of hypophosphatasia/HPP, and is a rare hereditary disorder affecting bone and dental mineralization. The program emerged from a joint venture between Rallybio and recurrence, and focused on the discovery and development of new and verbally available small molecule inhibitors of ENPP1 for HPP patients.

Close-up of a white lab coat and protective mask from the Biotechnology Institute.

REV102, a leading candidate for this collaboration, participated in the IND-Evenabling study in early 2025. Rallybio also receives a single-digit royalty low on all future net sales of REV102 due to recursion. Rallybio may also receive additional payments if it sells the Rev102 program to a third party.

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is a clinical stage biotechnology company that deciphers biology and chemistry by integrating innovations through biology, chemistry, automation, data science and engineering to industrialize US drug discoveries.

Rallybio Corporation (NASDAQ: RLYB) is a clinical stage biotechnology company that develops and commercializes conversion therapy for patients suffering from severe and rare diseases.

Although we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater promotion potential and pose a risk of decline. If you’re looking for a highly undervalued AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report. Best Short-Term AI Stocks.

Read next: 30 stocks that double in three years and 11 Hidden AI Strains Buy Now.

Disclosure: None. This article was originally published Insider Monkey.